Pfizer Cash on Hand 2010-2023 | PFE

Pfizer cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Pfizer cash on hand for the quarter ending December 31, 2023 was $12.690B, a 44.18% decline year-over-year.
  • Pfizer cash on hand for 2023 was $12.69B, a 44.18% decline from 2022.
  • Pfizer cash on hand for 2022 was $22.732B, a 26.83% decline from 2021.
  • Pfizer cash on hand for 2021 was $31.069B, a 154.18% increase from 2020.
Pfizer Annual Cash on Hand
(Millions of US $)
2023 $12,690
2022 $22,732
2021 $31,069
2020 $12,223
2019 $9,646
2018 $18,833
2017 $19,992
2016 $17,850
2015 $23,290
2014 $36,122
2013 $32,408
2012 $32,399
2011 $26,452
2010 $28,012
2009 $25,969
Pfizer Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $12,690
2023-09-30 $44,181
2023-06-30 $44,785
2023-03-31 $19,972
2022-12-31 $22,732
2022-09-30 $36,123
2022-06-30 $33,304
2022-03-31 $23,897
2021-12-31 $31,069
2021-09-30 $29,696
2021-06-30 $21,700
2021-03-31 $13,667
2020-12-31 $12,223
2020-09-30 $21,912
2020-06-30 $22,794
2020-03-31 $10,350
2019-12-31 $9,646
2019-09-30 $9,087
2019-06-30 $12,912
2019-03-31 $11,619
2018-12-31 $18,833
2018-09-30 $17,239
2018-06-30 $13,431
2018-03-31 $11,421
2017-12-31 $19,992
2017-09-30 $16,925
2017-06-30 $14,333
2017-03-31 $14,560
2016-12-31 $17,850
2016-09-30 $14,371
2016-06-30 $20,942
2016-03-31 $19,443
2015-12-31 $23,290
2015-09-30 $20,658
2015-06-30 $30,256
2015-03-31 $27,708
2014-12-31 $36,122
2014-09-30 $33,446
2014-06-30 $34,054
2014-03-31 $33,881
2013-12-31 $32,408
2013-09-30 $33,679
2013-06-30 $33,711
2013-03-31 $35,346
2012-12-31 $32,399
2012-09-30 $22,968
2012-06-30 $24,306
2012-03-31 $23,972
2011-12-31 $26,452
2011-09-30 $28,963
2011-06-30 $25,484
2011-03-31 $24,009
2010-12-31 $28,012
2010-09-30 $22,464
2010-06-30 $19,268
2010-03-31 $17,262
2009-12-31 $25,969
2009-09-30 $52,473
2009-06-30 $49,647
2009-03-31 $34,052
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $149.038B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $724.006B 120.57
Novo Nordisk (NVO) Denmark $560.627B 46.19
Johnson & Johnson (JNJ) United States $361.949B 14.40
Merck (MRK) United States $321.013B 84.50
AbbVie (ABBV) United States $299.292B 15.21
AstraZeneca (AZN) United Kingdom $211.169B 18.71
Novartis AG (NVS) Switzerland $200.048B 13.86
Sanofi (SNY) $119.220B 10.74
Innoviva (INVA) United States $0.923B 6.52